Apollomics Inc. (NASDAQ:APLM)
| Market Cap | $45.28M-8.6% |
| Revenue (ttm) | $0+199.1% |
| Net Income | -$7.22M+91.4% |
| EPS | -$2.48+30.0% |
| Shares Out | 2.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,067 |
| Open | $16.00 |
| Previous Close | $16.69 |
| Day's Range | $15.54 - $16.51 |
| 52-Week Range | $12.58 - $28.29 |
| Beta | 1.56 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Apr 1, 2027 |
About APLM
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Apr 1, 2027Earnings report
$APLM stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in APLM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by APLM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
APLM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New APLM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to APLM from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from APLM’s recent data — informational, not investment advice
